Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GX-E2 (Efepoetin alfa) in Healthy Male Subjects
NCT02291991Phase 1Completed
- Sponsor
- Genexine
- Start
- Nov 2014
- Primary completion
- Jan 2015
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of efepoetin alfa in anemia (2 arms), sponsored by Genexine. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 4 more. Started Nov 2014; status: completed.
02
Drugs
efepoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT02291991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02291991.